Healthcare / Pharmaceutical RetailersTokyo
$3220.00
+15.00 (+0.47%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 24% · confianza 25%
FCF escenarios
weak_data · normalized FCF $5.2B · quality 52.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
44/100
C
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$208.0B
P/E
12.6x
↓EV/EBITDA
6.0x
↓ROE
11.0%
↑Gross Margin
26.1%
↓Debt/Equity
N/A
•TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+9.2%
FCF CAGR
-10.8%
FCF margin
1.3%
FCF / Net income
0.38x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $457.09B · net income $15.69B · FCF $5.97B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $457.09B | $457.09B | $422.33B | $380.96B | $350.74B |
| Net Income | $15.69B | $15.69B | $13.69B | $12.93B | $12.60B |
| EBITDA | $28.30B | $28.30B | $25.23B | $23.27B | $22.16B |
| EPS | 242.82 | 242.82 | 215.61 | 204.46 | 199.24 |
| Gross Margin | 26.1% | 26.1% | 26.1% | 27.0% | 27.3% |
| Operating Margin | 5.0% | 5.0% | 4.8% | 5.0% | 5.2% |
| Net Margin | 3.4% | 3.4% | 3.2% | 3.4% | 3.6% |
| Balance Sheet | |||||
| Current Ratio | 1.27 | 1.27 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $5.97B | $5.97B | $5.22B | $2.68B | $8.42B |
| Returns | |||||
| ROE | 11.0% | 11.0% | 10.5% | 11.1% | 11.8% |
| Valuation | |||||
| P/E | 12.56 | 12.56 | 15.93 | 16.92 | 14.68 |
| EV/EBITDA | 6.01 | 6.01 | 7.13 | 7.79 | 6.45 |
| P/B | 1.46 | 1.46 | 1.67 | 1.88 | 1.74 |
| Growth & Yield | |||||
| Revenue Growth | 8.2% | 8.2% | 10.9% | 8.6% | — |
| EPS Growth | 12.6% | 12.6% | 5.5% | 2.6% | — |
| Dividend Yield | 2.8% | 2.8% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
5.6%
EPS terminal req.
$285.72
Spread vs growth
7.0%
5Y implied EPS CAGR
7.3%
EPS terminal req.
$345.72
Spread vs growth
5.3%
10Y implied EPS CAGR
8.7%
EPS terminal req.
$556.79
Spread vs growth
4.0%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+6.8%
Start / end P/E
14.4x → 13.3x
EPS bridge
215.61 → 242.82
Residual
-1.0%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.